Ultrasound assessment of the rectus femoris in patients with chronic obstructive pulmonary disease predicts poor exercise tolerance: an exploratory study

Mingming Deng¹²³⁴⁵, Chaonan Liang⁶, Yan Yin⁶, Jun Shu⁷, Xiaoming Zhou⁸, Qiuyue Wang⁶, Gang Hou¹²³⁴⁵ and Chen Wang¹²³⁴⁵⁹

Abstract

Background: Reduced exercise tolerance is an important clinical feature of chronic obstructive pulmonary disease (COPD) and is associated with poor prognosis. The 6-min walk test (6MWT) is widely used to assess exercise capacity; however, it is not commonly administered in primary medical institutions because it requires a suitable site and professional training. Ultrasound has great potential for evaluating skeletal muscle dimensions in COPD. However, whether skeletal muscle ultrasound can predict impaired exercise tolerance is unclear.

Methods: The study included 154 stable patients with COPD, who were randomly divided into a development set and a validation set. The thickness (RFthick) and cross-sectional area (RFcsa) of the rectus femoris were measured using ultrasound. Standardized RFthick (STD- RFthick) and Standardized RFcsa (STD-RFcsa) were obtained via standardization of RFthick and RFcsa by patients’ height.

Results: Strong correlations were observed between the 6MWD and RFthick (r = 0.84, p < 0.001) and between the 6MWD and RFcsa (r = 0.81, p < 0.001). In the development set, the optimal cut-off values for men and women for predicting poor exercise tolerance were < 3.098 cm/m and < 3.319 cm/m for STD-RFthick and < 4.052 cm²/m and < 4.366 cm²/m for STD-RFcsa, respectively. In the validation set, the area under the curve (AUC) values for the prediction of a 6MWD < 350 by STD-RFthick and STD-RFcsa were 0.881 and 0.903, respectively. Finally, the predictive efficacy of STD-RFthick (AUC: 0.922), STD-RFcsa (AUC: 0.904), and the derived nomogram model (AUC: 0.98) for exercise tolerance was superior to that of the sit-to-stand test and traditional clinical features.

Conclusions: Rectus femoris ultrasound has potential clinical application to predict impaired exercise tolerance in patients with COPD.

Keywords: COPD, Rectus femoris, Ultrasound, Exercise tolerance

Background

Chronic obstructive pulmonary disease (COPD) is the third most common cause of death globally [1]. In China, COPD is the fifth leading cause of death, with a reported prevalence of 13.7% in people aged ≥ 40 years [2, 3]. Reduced exercise tolerance is one of the main clinical features of COPD, and it is associated with increased...
frequency of acute exacerbations and all-cause mortality [4, 5].

The six-minute walk test (6MWT) is a common method of assessing exercise tolerance. In the 6MWT, patients walk as far as possible along a minimally trafficked 30-m corridor for a period of 6 min [6, 7]. A 6MWD < 350 m indicates impaired exercise tolerance and may predict a poor prognosis in COPD patients [8–10]. However, the 6MWT is difficult to administer in primary medical institutions because it requires an appropriate site (a 30-m flat course is required, and the layout of the track may influence the performance) [11, 12]. Establishing a screening method that is highly accurate, simple, and can be performed in primary medical facilities is therefore important.

The mechanism underlying reduced exercise tolerance in COPD patients is multifactorial [13]. Increasing evidence indicates that skeletal muscle dysfunction limit the exercise ability of patients and lead to impaired exercise tolerance [14, 15]. Identifying biomarkers related to skeletal muscle dysfunction may help predict exercise capacity in COPD patients. Recent study [16] has shown that the ultrasound assessment of the intercostal muscles can determine spirometry-related COPD severity. Ultrasound can also be used to estimate skeletal muscle dimensions of COPD patients [17, 18]. However, whether skeletal muscle ultrasound can predict impaired exercise tolerance remains unclear.

In this prospective study, we hypothesized that ultrasound of the rectus femoris could predict poor exercise tolerance in patients with COPD. Our aim was to build a nomogram based on ultrasound of the rectus femoris to predict poor exercise tolerance in patients with COPD. First, we measured skeletal muscle dimensions in COPD patients by ultrasound and analysed the correlations of the 6MWD with the thickness and cross-sectional area. In addition, we determined the cut-off values for thickness and cross-sectional area of the rectus femoris to predict impaired exercise tolerance (6MWD < 350 m). Finally, the nomogram model (combining traditional clinical features, STD-RF thick and STD-RF csa) was found to improve the predictive ability of impaired exercise tolerance.

Methods
Study design and patients
A total of 154 COPD patients (≥ 40 years old) from the First Hospital of China Medical University (Shenyang, China) were recruited for this prospective observational study between August 2018 and December 2019. The inclusion criterion was a diagnosis of stable COPD according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria. The exclusion criteria were as follows: COPD exacerbation within the last 1 month; presence of severe cardiovascular disease or active lung disease; concomitant disease affecting the musculoskeletal system; long-term systemic steroid therapy; and inability to read or understand the informed consent documents. Clinical features, including age, sex, height, and weight, were obtained from medical records. The study was approved by the research ethics committees of the First Hospital of China Medical University, and written informed consent was obtained from all patients.

Pulmonary function and assessment of modified British Medical Research Council (mMRC) scale and COPD Assessment Test (CAT)
Spirometry measurements (pre-bronchodilator) were performed following the American Thoracic Society and the European Respiratory Society guidelines using a Jaeger MasterScreen system (Jaeger, Viasys Healthcare GmbH, Hoechberg, Germany). Dyspnoea symptoms were measured using the Chinese version of the mMRC dyspnoea scale [19, 20], and health status was measured using the Chinese version of the CAT [21, 22].

Quadriceps muscle strength (QMS)
QMS was measured via a dynamometer (type: micro-FET2™; Hoggan, Salt Lake City, UT, USA) following the instructions in the manufacturer’s manual and previous studies [23, 24]. The knee of the patient was flexed to 90°, and the dynamometer plate was placed. The anterior end of the dynamometer was located 5 cm proximal to the lateral malleolus on the anterior surface of the leg and perpendicular to the long axis of the tibia. The participant was then instructed to generate a maximal knee extension force to hold the line in the same position for a duration of 4 s by pushing against the dynamometer plate to which the investigator applied increasing force with no encouragement (see Additional file 2: Fig. S2). The participant was then asked to generate a maximal knee extension force to hold the line in the same position for a duration of 4 s by pushing against the dynamometer plate to which the investigator applied increasing force with no encouragement. The same steps were repeated twice, with an intervening interval of 30–60 s. The average value of the last two assessments for each lower limb was recorded as the maximum unilateral contraction force. Then, the average contraction force on both sides was used to obtain the QMS.

Fat-free mass index (FFMI)
The participant’s body fat rate (BFR) was measured by a bioelectrical impedance meter (HBF-701, Omron, Japan). The FFMI was calculated as follows:
FFMI = weight (kg) × (1 − BFR)/height (m)².

Five-repetition sit-to-stand test (5STS) and the 30-s sit-to-stand test (30STS)
The participant was seated on a chair that measured 48 cm high and had no armrests, with their feet on the ground, back supported by the back of the chair, and hands folded in front of their chest. After hearing the test start command, the participant was asked to stand up and sit down 5 times as quickly as possible; the time needed to complete the 5 repetitions was recorded. During the test, participants were instructed to keep their arms crossed on the chest, and to completely straighten the knee joint when standing. The participant was given verbal encouragement during the test. The test was performed 3 times, with 1-min rest intervals. The average of 3 tests was recorded as the result. For the 30STS, the researcher recorded the number of times the participants stood up and sat down in 30 s. The test was repeated three times, and the average value was recorded as the result.

6MWT
According to the 2002 American Thoracic Society (ATS) guidelines [25], a closed, long, and straight 30-m indoor corridor was selected. The test method was explained to the patient before the test, and the patient was told to walk as much as possible. If they felt short of breath or experienced chest pain or dizziness, they were allowed to slow down or to stop to rest. If the above symptoms worsened and were not relieved after rest, the test was stopped immediately, and the patient was supervised by the experimenter and encouraged using standardized language. After 6 min, the patient heard the experimenter say “time is up”, which was their indication to stop. The test personnel recorded the distance travelled in metres.

Measurements of the thickness and cross-sectional area of the rectus femoris
Measurement of the quadriceps rectus femoris thickness and cross-sectional area was performed as in previous studies [26, 27]. Greyscale ultrasound was performed with an Aixplorer ultrasound scanning system (SuperSonic Imagine, Aix-en-Provence, France) with a 4- to 15-MHz linear-array transducer. The width of the linear-array transducer was 5 cm. The entire cross-sectional image of the rectus femoris in all patients were visualized via Aixplorer ultrasound scanning system. Our ultrasonographers received formal training, and with >10 years of experience. The patient did not engage in strenuous exercise for 72 h, rested quietly for 15 min and then laid on their back on the operating bed, relaxing all their muscles. The researchers set up a bracket to fix the ultrasound probe in place, thereby reducing muscle deformation due to external forces, and placed the ultrasound probe perpendicular to the patient’s dominant leg. The transducer was positioned perpendicular to the long axis of the dominant leg (precisely at 3/5 of the distance from the anterior superior iliac spine to the superior patellar border). This was the highest point in the thigh that the entire rectus femoris cross-section could be visualized in a single field in all subjects; other muscles of the quadriceps’s group could not be encompassed in this manner. The scanning depth was set such that the femur could be detected for orientation. Gentle contraction-relaxation manoeuvres were employed to delineate the muscle septum prior to image acquisition. RFthick and RFcsa were calculated after the inner echogenic line of the rectus femoris was outlined by a movable cursor on a frozen image (Fig. 1). RFthick and RFcsa were recorded as the averages of three consecutive measurements within 10%.

Construction of the nomogram and decision curve analysis
A nomogram is an intuitive and effective method of displaying the results of a risk model. It was constructed using the R package “rms”. Decision curve analysis was used to decide whether the predictive nomogram was clinically useful.

Statistical analyses
Statistical analyses were performed using SPSS 13.0 software (IBM, Armonk, NY, USA). Continuous variables are expressed as the median values and IQRs, as well as the minimum and maximum values. Spearman correlation coefficient analysis was used to compare the correlations of the RFthick and RFcsa with the clinical features of COPD.
patients. The differences in the RF\textsubscript{thick} and RF\textsubscript{csa} between men and women were determined using unpaired t tests, and p-values <0.05 were considered statistically significant. Receiver operating characteristic (ROC) curve analysis and the area under the curve (AUC) were used to determine the optimal cut-off values for STD-RF\textsubscript{thick}, STD-RF\textsubscript{csa} and the STST results for the prediction of a 6MWD < 350 m.

Results
Patient characteristics
A total of 154 patients were enrolled in the final analysis. The baseline characteristics of the patients are listed in Table 1. The range of FEV\textsubscript{1}\% of our patients is 30.1–110.6%. Our study population included patients of different severity, and it doesn’t limit the external validity of the study.

Relationships of quadriceps thickness (RF\textsubscript{thick}) and quadriceps cross-sectional area (RF\textsubscript{csa}) with the clinical features of COPD patients
The relationships of RF\textsubscript{thick} and RF\textsubscript{csa} with the clinical features were analysed. As shown in Fig. 2A, the 6MWD features were analysed. As shown in Fig. 2A, the 6MWD features of COPD patients were negatively correlated with RF\textsubscript{thick} and RF\textsubscript{csa}; the CAT score (r\textsuperscript{p} = -0.428, p\textless 0.001) were negatively correlated with RF\textsubscript{csa}. The 6MWD showed significant strong positive correlations with RF\textsubscript{thick} (Fig. 2B) and RF\textsubscript{csa} (Fig. 2C).

Analysis and validation of STD-RF\textsubscript{thick} and STD-RF\textsubscript{csa} as predictors of poor exercise tolerance
A total of 154 COPD patients were randomly assigned to a development set and a validation set at a ratio of 7:3 (Table 2). Because RF\textsubscript{csa} and RF\textsubscript{thick} differed between men and women (Additional file 1: Fig. S1), we performed ROC analysis in men and women separately to evaluate the predictive ability of RF\textsubscript{thick} and RF\textsubscript{csa} for poor exercise tolerance. And, Next, we standardized RF\textsubscript{thick} and RF\textsubscript{csa} by patients’ height, and obtained STD-RF\textsubscript{thick} and STD-RF\textsubscript{csa}. The ROC curves derived from the development set demonstrating the ability of skeletal muscle ultrasound to predict impaired exercise tolerance based on STD-RF\textsubscript{thick} and STD-RF\textsubscript{csa} are shown in Fig. 3A. In male COPD patients, the sensitivity and specificity for predicting a poor 6MWD based on STD-RF\textsubscript{thick} were 91.3% and 88.24%, respectively (the cut-off point was 3.098 cm/m and the AUC was 0.951), and the sensitivity and specificity for predicting a poor 6MWD based on STD-RF\textsubscript{csa} were 86.96% and 88.24%, respectively (the cut-off point was 3.319 cm/m and the AUC value was 0.947). In female patients, the sensitivity and specificity for predicting a poor 6MWD based on STD-RF\textsubscript{thick} were 94.12% and 100%, respectively (the cut-off point was 3.319 cm/m and the AUC value was 0.971), and those for predicting a poor 6MWD based on STD-RF\textsubscript{csa} were 94.12% and 100%, respectively (the cut-off point was 6.940 cm/m and the AUC value was 0.963).

In the validation set (Fig. 3B), the sensitivity was 94.74% and the specificity was 81.48% for detecting a 6MWD < 350 m with STD-RF\textsubscript{thick} (AUC value: 0.881), whereas the sensitivity and specificity for predicting a poor 6MWD based on STD-RF\textsubscript{thick} were 84.21% and 96.30%, respectively (AUC value: 0.903).

Table 1 Patient characteristics

| Overall | n 154 |
|---------|------|
|         |      |
| Sex/male (%) | 64 (41–83) |
| FEV\textsubscript{1} (L) | 15.06 (0.45–3.1) |
| FEV\textsubscript{1}/FVC | 0.85 (30.1–110.6) |
| FVC (L) | 3.00 (0.92–5.21) |
| FVC% pred | 80.82 (34.4–123.8) |
| FEV\textsubscript{1}/FVC | 0.59 (81–68.98) |
| RV (L) | 4.06 (1.34–7.31) |
| TLC (L) | 6.44 (3.52–9.84) |
| RV/TLC (%) | 73.69 (31–242.4) |
| BMI (kg/m\textsuperscript{2}) | 23.92 (11.3–37.3) |
| FFMI (kg/m\textsuperscript{2}) | 17.00 (9.5–23.8) |
| Height (cm) | 165.41 (141–180) |
| Weight (Kg) | 65.07 (26.7–110.4) |
| mMRC | 2 (0–4) |
| CAT | 15 (0–37) |
| RF\textsubscript{thick} (cm) | 5.46 (4.5–6.97) |
| RF\textsubscript{csa} (cm\textsuperscript{2}) | 7.05 (6.01–8.28) |
| 6MWD (m) | 369 (108–554) |
| QMS (kg) | 42.91 (21.55–68.1) |

FEV\textsubscript{1}, Forced Expiratory Volume in the first second; FEV\textsubscript{1}/FVC, FEV\textsubscript{1} percentage predicted; FVC, forced vital capacity; FVC% pred, FVC percentage predicted; RV, residual volume; TLC, total lung capacity; BMI, body mass index; FFMI, fat-free mass index; CAT, COPD Assessment Test; 6MWD, 6-min walk distance; QMS, quadriceps muscle strength.
Comparison of the predictive efficacy of skeletal muscle ultrasound and the STST

The results from our group [24] and other studies [28–30] indicate that the STST can be used as a primary screening test to evaluate exercise tolerance in COPD patients. Therefore, we compared the efficacy of the STST to that of the STD-RF\textsubscript{thick} and STD-RF\textsubscript{csa} derived from skeletal muscle ultrasound in 154 COPD patients for predicting a poor 6MWD. As shown in Fig. 4, the AUC values for the 30STS score, 5STS score, STD-RF\textsubscript{csa}, and STD-RF\textsubscript{thick} were 0.712, 0.724, 0.904, and 0.922, respectively. The sensitivities of the 30STS score, 5STS score,
STD-RF\textsubscript{thick} and STD-RF\textsubscript{csa} were 70.97%, 82.86%, 96.61%, and 77.97%, respectively, whereas the specificities were 68.63%, 44.12%, 67.74%, and 89.25%, respectively. The above results showed that the levels of predictive power of STD-RF\textsubscript{thick} and STD-RF\textsubscript{csa} were higher than those of the STSTs.

### Construction of a nomogram to predict impaired exercise tolerance

Exercise tolerance is affected by many factors, and has the complex mechanisms. Previous studies [31–33] have shown that Age, BMI, and pulmonary function are effective predictors of poor exercise tolerance in COPD. The Nomogram model could comprehensively incorporate the effects of diverse clinical factors. A nomogram model was constructed to predict impaired exercise tolerance (6MWD < 350 m) in COPD patients based on traditional clinical features, STD-RF\textsubscript{thick} and STD-RF\textsubscript{csa} (Fig. 5A). The performance of our model was confirmed via a calibration plot (Fig. 5B). Furthermore, the nomogram model had a higher AUC value than individual variables based on the results of the ROC analysis (Fig. 5C). Finally, the combined nomogram model had the highest efficacy for the prediction of a 6MWD < 350 m according to decision curve analysis (Fig. 5D). These results confirmed the potential clinical value of our nomogram model.

### Discussion

Ultrasound is a non-invasive technique that can be used to assess the physical condition of COPD patients and severity of COPD based on imaging of different areas, including the intercostal muscles and skeletal muscles [34, 35]. In this study, the thickness and cross-sectional area of the rectus femoris determined via ultrasound were correlated with the clinical features of COPD patients, including pulmonary function, clinical symptoms, and exercise tolerance. STD-RF\textsubscript{thick} and STD-RF\textsubscript{csa} predicted poor exercise tolerance more effectively than the STSTs. A nomogram model constructed based on

### Table 2 Patient characteristics of development set and validation set

| Development set | Validation set | P value |
|-----------------|----------------|---------|
| n               | 108            | 46      |
| Age (years)     | 64 (41–81)     | 65 (54–83) | 0.62 |
| Sex/male (%)    | 75 (69)        | 33 (72)  | 0.926 |
| FEV\textsubscript{1} (L) | 1.54 (0.45–3.1) | 1.63 (0.63–2.9) | 0.424 |
| FEV\textsubscript{1} % pred | 58.12 (15.8–99.5) | 62.38 (30.1–110.6) | 0.263 |
| FVC (L)         | 2.79 (0.98–5.21)| 2.82 (0.92–4.75)| 0.852 |
| FVC % pred      | 80.14 (34.4–119.6) | 82.72 (49.2–123.8) | 0.671 |
| FEV\textsubscript{1}/FVC   | 54.00 (31–68.59) | 57.16 (32–68.98) | 0.082 |
| RV (L)          | 4.12 (1.97–7.31)| 3.90 (1.34–6.43)| 0.608 |
| TLC (L)         | 6.55 (3.88–9.84)| 6.14 (3.52–8.72)| 0.316 |
| RV/TLC (%)      | 75.58 (39–242.4)| 68.53 (31–149.2)| 0.522 |
| BMI (kg/m\textsuperscript{2}) | 24.10 (11.3–37.3) | 23.48 (17.2–30) | 0.357 |
| FFMI (kg/m\textsuperscript{2}) | 17.09 (9.5–23.8) | 16.78 (11.8–19.3) | 0.461 |
| Height (cm)     | 165.42 (141–180) | 165.40 (147–177) | 0.991 |
| Weight (Kg)     | 65.84 (26.7–110.4) | 63.26 (40.2–90.3) | 0.323 |
| mMRC             | 2 (0–4)        | 2 (0–4)  | 0.599 |
| RF\textsubscript{thick} (cm) | 5.48 (4.51–6.97) | 5.41 (4.5–6.96) | 0.515 |
| RF\textsubscript{csa} (cm\textsuperscript{2}) | 7.06 (6.01–8.22) | 7.03 (6.06–8.28) | 0.78 |
| 6MWD (m)        | 370.8 (108–554) | 365.9 (177–510) | 0.721 |
| QMS (kg)        | 42.89 (21.55–68.1) | 42.94 (24.2–65.05) | 0.986 |

FEV\textsubscript{1}, Forced Expiratory Volume in the first second; FEV\textsubscript{1} % pred, FEV percentage predicted; FVC, forced vital capacity; FVC % pred, FVC percentage predicted; RV, residual volume; TLC, total lung capacity; BMI, body mass index; FFMI, fat-free mass index; CAT, COPD Assessment Test; 6MWD, 6-min walk distance; QMS, quadriceps muscle strength.

STD-RF\textsubscript{csa} and STD-RF\textsubscript{thick} were 70.97%, 82.86%, 96.61%, and 77.97%, respectively, whereas the specificities were 68.63%, 44.12%, 67.74%, and 89.25%, respectively. The above results showed that the levels of predictive power

---

![Fig. 3](image-url)  
**Fig. 3** Receiver operating characteristic curve analysis of STD-RF\textsubscript{thick} and STD-RF\textsubscript{csa} for the prediction of poor exercise tolerance (6MWD < 350 m) in the development set (A) and the validation set (B).
RF\textsubscript{thick}, RF\textsubscript{csa}, and clinical features may help physicians with decision-making.

Skeletal muscle dysfunction, which is present in 1/3 of COPD patients and is more common in patients with severe disease, can affect both ventilatory and nonventilatory muscles, leading to a poor prognosis [36, 37]. Ultrasound is a promising tool for use in clinical practice to estimate skeletal muscle dimensions in COPD patients by measuring the thickness and cross-sectional area of skeletal muscles [17, 18]. We analysed a larger number of patients in this study than previous studies, and the results showed that RF\textsubscript{thick} and RF\textsubscript{csa} were related to clinical features (including pulmonary function, symptoms, and exercise tolerance) in COPD patients. These results indicated that rectus femoris ultrasound may be a useful method of assessing disease severity in COPD patients.

In this study, results showed that STD-RF\textsubscript{thick} and STD-RF\textsubscript{csa} had the highest AUC values, sensitivities, and specificities, suggesting that they are more valuable predictors of a poor 6MWD than the 5STS and 30STS. Furthermore, the constructed nomogram model further improved the predictive ability to identify patients with impaired exercise tolerance (AUC: 0.98) and is much more visual.

The results of our study suggest that ultrasound measurements of the rectus femoris in patients with COPD have potential clinical value in the prediction of exercise limitation. However, we must note that ultrasound measurements provide only a partial quantification of muscle dimensions. 6MWD is a well-established and validated parameter in COPD patients, that is associated with daily activity, severity of disease, and prognosis [6]. Prediction of 6MWD < 350 m through the quantification of muscle dimensions via ultrasound measurements still need more external data verification. In additional, sarcopenia, which includes both loss of muscle mass and function, has been recognized as a syndrome in patients with COPD [38, 39]. Ultrasound measurements of skeletal muscle may have potential value in the prediction of sarcopenia in these patients.

The present study has several limitations. 1, It should be considered as exploratory because participants were all from Northern China. Caution should be taken when extrapolating the clinical application of rectus femoris ultrasound to other ethnicities. 2, Most of our patients were male which reflects the higher prevalence of COPD in men (11.9%) than in women (5.4%) in China [3]. 3, Lack of a healthy control group. A previous study [18] indicates that mean RF\textsubscript{csa} is reduced in patients with COPD by 25% of the mean value in healthy subjects. 4, Whether ultrasound assessment of the rectus femoris could predict exercise tolerance in healthy subjects is unclear. One study [40] conducted in older heathy men found that a greater change in muscle width corresponded to faster walking speeds, suggesting a link between muscular dimensional changes and performance during dynamic activities. Based on these previous reports, future studies are needed to determine the clinical value of ultrasound assessment of the rectus femoris in healthy subjects. 5, Lack of the data of the reproducibility of the measures for different observers is the major limitation of this study. Previous study [41] about rectus femoris ultrasound measurements in 17 men with COPD showed that differences in cross-sectional area of the rectus recorded by two experienced operators in patients with COPD were not significant. Specifically, determination coefficient (0.99) and correlation coefficients (0.998) between cross-sectional area of the rectus recorded by two experienced operators in patients with COPD were high. And, the error of measurements (0.06 ± 0.03 cm, \( p = 0.94 \)) and percentage errors were small (1.4%). Overall, that study [41] has determined the reproducibility and reliability of measurements obtained by experienced operators. Thus, the assessment of RF\textsubscript{thick} and RF\textsubscript{csa} by ultrasound also necessitates training and must to be performed by treating physicians or trained radiologists. Future studies are needed to further verify the reproducibility of ultrasound and the standardized operation of ultrasound. 6, The study was limited to clinically stable patients with COPD. Whether the findings can be applied to patients with acute exacerbations of COPD and those undergoing pulmonary rehabilitation remains to be determined. These issues will be investigated in a future study.
Conclusions

Based on the measurement of ultrasound, thickness of the rectus femoris standardized by patients’ height (3.098 cm/m for men, 3.319 cm/m for women) and cross-sectional area of the rectus femoris standardized by patients’ height (4.052 cm²/m for men, 4.366 cm²/m for women) have potential for the clinical assessment of exercise intolerance in patients with COPD.

Abbreviations
COPD: Chronic obstructive pulmonary disease; 6MWT: The 6-min walk test (6MWT); RFthick: The thickness of the rectus femoris; RFcsa: The cross-sectional area of the rectus femoris; STD-RFthick: Standardized the thickness of the rectus femoris; STD-RFcsa: Standardized the cross-sectional area of the rectus femoris; AUC: The area under the curve; 6MWD: 6-Min walk distance; mMRC: Modified British Medical Research Council; CAT: COPD Assessment Test; QMS: Quadriceps muscle strength; FFMI: Fat-free mass index; 5STS: Five-repetition sit-to-stand test; 30STS: The 30-s sit-to-stand test.

Fig. 5 Construction of a nomogram model. A A nomogram was constructed to predict poor exercise tolerance (6MWD < 350 m) in COPD patients. B Calibration curves for the nomogram for the prediction of poor exercise tolerance (6MWD < 350 m) in COPD patients. C ROC curve analysis showing that the highest AUC value corresponded to the nomogram model. D Decision curve analysis showing the net benefit of the nomogram model for the prediction of poor exercise tolerance (6MWD < 350 m)
Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12890-021-01663-8.

Additional file 1: Fig. 1. The difference of ultrasound assessment of the rectus femoris in men and women. The RF_{mucc} (A) and RF_{csa} (B) differed between men and women. *P < 0.05.

Additional file 2: Fig. 2. The process of using the dynamometer. Measurement of quadriceps muscle strength via dynamometer.

Acknowledgements
Not applicable.

Authors’ contributions
CW and GH designed the study. MD and GH wrote the manuscript. CL, YY, JS, XZ, QW contributed to data collection and data analysis. All authors read and approved the final manuscript.

Funding
This research was supported by the Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences (No. 2020-PT320-001), National Natural Science Foundation of China (No. 81900040), Liaoning Education Ministry Supporting Foundation (No. QN2019014), and Liaoning Science and Technology Ministry Supporting Foundation (No.2019-ZD-0766).

Availability of data and materials
All data generated or analysed during this study are included in this published article.

Declarations
Ethics approval and consent to participate
All procedures performed in studies involving human participants were in accordance with the Declaration of Helsinki. And this study was approved by the research ethics committees of the First Hospital of China Medical University [No.2018-144-2]. Written informed consent was obtained from all participants in this study.

Consent for publication
Not applicable.

Competing interests
The authors have declared that no competing interest exists.

Author details
1Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing 100029, China. 2Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100029, China. 3Institute of Clinical Medical Science, Chinese Academy of Medical Sciences, Beijing 100029, China. 4Institute of Clinical Medical Science, China-Japan Friendship Hospital, Beijing 100029, China. 5Department of Pulmonary and Critical Care Medicine, First Hospital of China Medical University, Shenyang 110001, China. 6Institute of Clinical Medical Science, China-Japan Friendship Hospital, Beijing 100029, China. 7Department of Pulmonary and Critical Care Medicine, Fourth Hospital of China Medical University, Shenyang 110001, China. 8Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100029, China.

Received: 27 April 2021 Accepted: 1 September 2021
Published online: 25 September 2021

References
1. Rabe KF, Watz H. Chronic obstructive pulmonary disease. Lancet (London, England). 2017;389(10082):1931–40.
2. Zhou M, Wang H, Zeng X, Yin P, Zhu J, Chen W, Li X, Wang L, Wang L, Liu Y, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet (London, England). 2019;394(10204):1145–58.
3. Wang C, Xu J, Yang L, Xu Y, Zhang X, Bai C, Kang J, Ran P, Shen H, Wen F, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. Lancet (London, England). 2018;391(10131):1706–17.
4. Riley CM, Scurfa FC. Diagnosis and outpatient management of chronic obstructive pulmonary disease: a review. JAMA. 2019;321(8):786–97.
5. Maltais F, Decramer M, Casaburi R, Barreiro E, Burelle Y, Debهجار R, Dejhuiuen PNR, Franssen F, Ganyan-Ramirez G, Gea J, et al. An official American Thoracic Society/European Respiratory Society statement: update on limb muscle dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2014;189(9):e15–62.
6. Agarwala P, Salzman SH. Six-minute walk test: clinical role, technique, coding, and reimbursement. Chest. 2020;157(3):603–11.
7. Papaioannou AI, Loukides S, Gourgoulianis KI, Kostikas K. Global assessment of the COPD patient: time to look beyond FEV1? Respir Med. 2009;103(5):650–60.
8. Puhani MA, Mador MJ, Held U, Goldstein R, Guyatt GH, Schünemann HJ. Interpretation of treatment changes in 6-minute walk distance in patients with COPD. Eur Respir J. 2008;32(6):637–43.
9. Pinto-Plata VM, Cote C, Cabral H, Taylor J, Celis BR. The 6-min walk distance: change over time and value as a predictor of survival in severe COPD. Eur Respir J. 2004;23(1):28–33.
10. Casanova C, Cote CG, Marin JM, de Torres JP, Aguierre-Jaime A, Mendez R, Dordelly L, Celis BR. The 6-min walking distance: long-term follow up in patients with COPD. Eur Respir J. 2007;29(3):535–40.
11. Cote CG, Pinto-Plata V, Kasprzyk K, Dordelly L, Celis BR. The 6-min walk distance, peak oxygen uptake, and mortality in COPD. Chest. 2007;132(6):1778–85.
12. Scurfa C, Criner GJ, Lee SM, Mohsenifar Z, Shade D, Sliwka W, Wise RA. Six-minute walk distance in chronic obstructive pulmonary disease: reproducibility and effect of walking course layout and length. Am J Respir Crit Care Med. 2003;167(11):1522–7.
13. Seymour JM, Ward K, Sidhu PS, Puthucheary Z, Steier J, Jolley CJ, Rafferty G, Polkey MI, Moxham J. Ultrasound measurement of rectus femoris muscle thickness in COPD patients. Int J Chron Obstruct Pulmon Dis. 2017;12:3007–15.
14. Sin DD, Man SFP. Skeletal muscle weakness, reduced exercise tolerance, and COPD: is systemic inflammation the missing link? Thorax. 2006;61(1):1–3.
15. Barreiro E, Gea J. Respiratory and limb muscle dysfunction in COPD. COPD. 2015;12(4):413–26.
16. Wallbridge P, Parry SM, Das S, Law C, Hammerschlag I, Irving L, Hew M, Steinfort D. Parasternal intercostal muscle ultrasound in chronic obstructive pulmonary disease correlates with spirometric severity. Sci Rep. 2018;8(1):15274.
17. Ye X, Wang M, Xiao H. Echo intensity of the rectus femoris in stable COPD patients. Int J Chron Obstruct Pulmon Dis. 2017;12:2007–15.
18. Seymour JM, Ward K, Siddhi PS, Puthucheary Z, Steier J, Lolley CJ, Rafferty G, Polkey MI, Moxham J. Ultrasound measurement of rectus femoris cross-sectional area and the relationship with quadriceps strength in COPD. Thorax. 2009;64(5):418–23.
19. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54(7):581–6.
20. Cui L, Ji X, Xie M, Dou S, Wang W, Xiao W. Role of inspiratory capacity on dyspnea evaluation in COPD with or without emphysema-tomatous lesions: a pilot study. Int J Chron Obstruct Pulmon Dis. 2017;12:2823–30.
21. Zhou Q-t, Mei J-j, He B, Huang S-g, Shi Y, Wen F-q, Zhao M-w. Chronic obstructive pulmonary disease assessment test score correlated with dyspnea score in a large sample of Chinese patients. Chin Med J. 2013;126(1):11–5.
22. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009;34(3):648–54.
23. O’Shea SD, Taylor NF, Paratz JD. Measuring muscle strength for people with chronic obstructive pulmonary disease: retest reliability of hand-held dynamometry. Arch Phys Med Rehabil. 2007;88(1):32–6.

24. Zhang Q, Li Y-X, Li X-L, Yin Y, Li R-L, Qiao X, Li W, Ma H-F, Ma W-H, Han Y-F, et al. A comparative study of the five-repetition sit-to-stand test and the 30-second sit-to-stand test to assess exercise tolerance in COPD patients. Int J Chron Obstruct Pulmon Dis. 2018;13:2833–9.

25. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002, 166(1):111–117.

26. Maynard-Paquette A-C, Poirier C, Chartrand-Lefebvre C, Dubé B-P. Ultrasound evaluation of the quadriceps muscle contractile index in patients with stable chronic obstructive pulmonary disease: relationships with clinical symptoms, disease severity and diaphragm contractility. Int J Chron Obstruct Pulmon Dis. 2020;15:79–88.

27. Shrirkrishna D, Patel M, Tanner RJ, Seymour JM, Connolly BA, Puthucheary ZA, Walsh SLF, Bloch SA, Sadhu PS, Hart N, et al. Quadriceps wasting and physical inactivity in patients with COPD. Eur Respir J. 2012;40(5):1115–22.

28. Jones SE, Kon SSC, Canavan JL, Paten J, Clark AL, Nolan CM, Polkey MJ, Man WDC. The five-repetition sit-to-stand test as a functional outcome measure in COPD. Thorax. 2013;68(11):1015–20.

29. Bernabeu-Mora R, Medina-Mirapeix F, Llamazares-Herrán E, García-Guillamón G, Gménez-Gménez LM, Sánchez-Nieto JM. The Short Physical Performance Battery is a discriminative tool for identifying patients with COPD at risk of disability. Int J Chron Obstruct Pulmon Dis. 2015;10:2619–26.

30. Monta AA, Bisca GW, Machado FVC, Hernandes NA, Pita F, Probst VS. Best protocol for the sit-to-stand test in subjects with COPD. Respir Care. 2018;63(8):1040–9.

31. Schoos MW, Dalsgaard M, Kjaergaard J, Moeby D, Jensen SG, Steffensen I, Iversen KK. Echocardiographic predictors of exercise capacity and mortality in chronic obstructive pulmonary disease. BMC Cardiovasc Disord. 2013;13:84.

32. Díaz AA, Pinto-Plata V, Hernández C, Peña J, Ramos C, Díaz JC, Klaassen J, Patino CM, Salidas F, Díaz O. Emphysema and DLCO predict a clinically important difference for 6MWD decline in COPD. Respir Med. 2015;109(7):882–9.

33. Spieshofer J, Henke C, Kabitz HJ, Nofke JR, Mohr M, Evers G, Strecke JK, Brix T, Randerath WJ, Herkenrath S, et al. Respiratory muscle and lung function in lung allograft recipients: association with exercise intolerance. Respiration Int Rev Thoracic Dis. 2020;99(5):398–408.

34. Radzina M, Biederer J. Ultrasonography of the Lung. Rofa. 2019;19(10):909–23.

35. Petrou N, Talbot NP, Pavord IJ. Measuring lung function in airways diseases: current and emerging techniques. Thorax. 2019;74(8):797–805.

36. Maddocks M, Shrirkrishna D, Viteriano S, Nataneke SA, Tanner RJ, Hart N, Kemp PR, Moxham J, Polkey MI, Hopkinson NS. Skeletal muscle adiposity is associated with physical activity, exercise capacity and fibre shift in COPD. Eur Respir J. 2014;44(5):1188–98.

37. Cruthirds CL, van der Meij BS, Wierczowska-McNew A, Deutz NEP, Engelen MKJ. Presence or absence of skeletal muscle dysfunction in chronic obstructive pulmonary disease is associated with distinct phenotypes. Arch Bronconeumol. 2020;57:264–72.

38. Cruz-Jentoft AJ, Sayer AA. Sarcopenia. Lancet (London, England). 2019;393(10191):2636–46.

39. Sepúlveda-Loyola W, Osiadnik C, Phu S, Morita AA, Duque G, Probst VS. Diagnosis, prevalence, and clinical impact of sarcopenia in COPD: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2020;11(5):1164–76.

40. Giuliani HK, Shea NW, Gerstner GR, Mota JA, Blackburn JT, Ryan ED. The influence of age and obesity-altered muscle tissue composition on muscular dimensional changes: impact on strength and function. J Gerontol A Biol Sci Med Sci. 2020;75(12):2286–94.

41. Hammond K, Mampilly J, Laghi FA, Goyal A, Collins EG, McBurney C, Jubb H, Tobin MJ. Validity and reliability of rectus femoris ultrasound measurements: comparison of curved-array and linear-array transducers. J Rehabil Res Dev. 2014;51(7):1155–64.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.